INTRODUCTION
Although infection of mice with murine cytomegalovirus (MCMV) elicits an antibody response, the role of antibody in recovery from MCMV infection is unresolved. Some investigators have not detected neutralizing antibody until 14 to 26 days post-infection (p.i.) (Medearis, 1964; Quinnan & Manischewitz, 1987) , but others have demonstrated neutralizing antibody by 3 clays p.i. using a sensitive complement-dependent neutralization assay (Kim & Carp, 1973; Araullo-Cruz et al., 1978) and have shown that this early serum passively protects mice against MCMV infection (Araullo-Cruz et al., 1978) . Virus-specific immunoglobulin rather than interferon was identified as the protective serum factor. Furthermore, decreased MCMV replication has been associated with the presence of maternal antibody to MCMV in suckling mice (Medearis & Prokay, 1978) , and mice in which immunoglobulin synthesis was inhibited by treatment with goat anti-mouse IgM serum from birth were 10-fold more susceptible to MCMV than normal mice (Selgrade et al., 1976) .
In addition to the protection that may be afforded by specific immunological mechanisms, the resistance of mice to MCMV is also influenced by H-2-and non-H-2-1inked genes [Chalmer et al., 1977 (Shellam et al., 1981 . Although death of susceptible mice as early as 2 to 3 days p.i. suggests that an early mechanism, rather than the humoral or cell-mediated immune response, protects resistant strains the role of antibody has not been elucidated. In order to approach this problem we have hypothesized that if antibody were important, higher titres and earlier production of antibodies to MCMV would be a characteristic of genetically resistant mouse strains. Accordingly, we have investigated the kinetics of production of IgM, IgG and IgA antibody to MCMV in a variety of inbred mouse strains of differing resistance status. The protective effect of anti-MCMV antibody from resistant and susceptible mice was also tested by passive transfer to susceptible recipients challenged with MCMV.
METHODS
Mice. Highly inbred, specific pathogen-free, mice were obtained from the Animal Resources Centre, (Murdoch, Western Australia) and housed under minimal disease conditions. The strains used, with their respective haplotypes and relative LDso values given in parentheses [Grundy (Chalmer) et al., 1981 ; Bancroft et al., 1981 ; Allan & Shellam, 1984] were BALB/c (H-2 d, 1-0 LDs0), BALB.K (H-2 k, 8 to 12LD5o), BALB.B (H-2 b, I'0LDs0), A/J (H-2 a, 0.5LDso), CBA/CaH (CBA; H-2 k, 24 to 28LD50), C57BL/10ScSn (B10; H-2 b, 2 to4 LDso), B10.A (H-2 a, 3.8 LDs0), B10. D2 (H-2 d, 2 to4 LDs0) and B10. BR (H-2 k, 32 to 36 LDs0 ). The relative LDs0 value refers to the LDso of MCMV in the tested mouse strain compared with that in BALB/c mice which is arbitrarily assigned the value of 1.0. Thus a relative LDso of tO indicates that the LDso in that strain is 10 times the virus dose for 1.0 LDso in the BALB/c strain. All LD50 values of virus quoted in this paper refer to those of BALB/c mice. Female mice of 8 weeks of age were inoculated by the intraperitoneal (i.p.) route with 0.1 ml of a suspension of live salivary gland-derived MCMV in phosphate-buffered saline with an osmolarity adjusted to be equivalent to that of mouse serum (MOBS; 330 mosM), unless otherwise stated.
Cell cultures. Mouse embryonic fibroblast (MEF) cultures were prepared by trypsin dispersion of 14-to 15-dayold embryos from outbred CD1 mice and were passaged in Eagle's MEM (EMEM, Gibco) and 10% foetal calf serum (FCS) as described elsewhere (Lawson et al., 1987) .
Virus. MCMV (Smith strain) was originally obtained from Dr D. J. Lang (Duke University, Durham, N.C., U.S.A.). The virus was maintained in this laboratory by passage in weanling female BALB/c mice as described elsewhere (Lawson et al., 1987) . Attenuated MCMV was prepared by one passage in MEF (Osborn & Walker, 1970) . Inactivated MCMV was exposed to u.v. light (800 ~tW/cm 2) for 4 min and was found to be non-infectious as detected by the plaque assay. For the preparation of MCMV antigen used in ELISA, confluent primary MEF cultures were washed three times in MOBS before infection with virulent salivary gland-derived MCMV (m.o.i. 1.0) diluted in EMEM supplemented with 2~ FCS. After virus adsorption for 1 h at 37 °C in 10% CO~, the inoculum was removed and replaced with EMEM and 2~ FCS. When 20~ of the cells showed c.p.e., they were washed three times with MOBS and cultured in serum-free EMEM with incubation at 37 °C in 10~ CO2. The supernatant was collected daily and stored at -20 °C, until the monolayer disintegrated. Uninfected cell monolayers served as controls. Pooled supernatants were clarified by centrifugation at 4500g and 4 °C for 20 min followed by ultracentrifugation at 30000 g and 4 °C for 2 h. The virus pellet was resuspended in 4 ~ of the original volume with MOBS and stored at -70 °C.
To prepare trypsin-treated virus, both virulent and attenuated virus preparations were treated with trypsin (5 or 10 p.g/ml, Difco) at 37 °C for 20 rain. Then the mixture was cooled on ice and the activity of trypsin terminated by the addition of 10~ FCS (Inada & Mires, 1985) .
Plaque assay. Details of the plaque assay for MCMV are described elsewhere (Lawson et al., 1987) . MEF monolayers were infected with virus samples including organ homogenates (10~ w/v in MEM and 2~ FCS) that were prepared at 4 °C and centrifuged at 2000 g for 20 rain at 4 °C and stored at -70 °C until use. After incubation for 5 days at 37 °C in 10~ CO2 the cells were stained with 1~ methylene blue containing 10~ formalin. A standard virus of known titre was processed in parallel with the test virus. An estimate of the variation of the plaque assay data using analysis of variance was performed using eight replicates on four separate days. The expected S.E.M. of triplicate samples was + 7"8% of the mean value.
Serum collection. Blood samples were obtained from mice while under ether anaesthesia. The blood was allowed to clot at room temperature for 30 min followed by centrifugation at 900 g for 10 min. Sera were stored at -70 °C. For the preparation of hyperimmune serum, BALB/c mice were inoculated with 103 p,f.u, and given booster injections (104 p.f.u.) by the i.p. route every 10 days for 30 days. Immunoglobulin fractions of immune sera were prepared by ammonium sulphate precipitation followed by dialysis in MOBS (Heidi & Schwich, 1978) and were diluted to the same ELISA titre prior to use in the passive transfer experiments. Several sources of sera were used for their complement activity including lyophilized guinea-pig complement (CSL, Melbourne, Australia), fresh guinea-pig, mouse and rabbit sera. The fresh sera were obtained from blood collected at 4 °C and centrifuged at 900g for t0 rain at 4 °C before being stored frozen at -70 °C until use.
ELISA. The ELISA used was a modification of the method used by Shanley eta!. (1981) . MCMV antigen was diluted to optimum concentration with carbonate/bicarbonate buffer pH 9-6 and incubated at 4 °C for 24 h in 96-well plates (Linbro, EIA microtitration plates, Flow Laboratories). Plates were washed three times with MOBS containing 0-05~ Tween 20 (Sigma) and 0-1 ~ bovine serum albumin (BSA; CSL) between all additions of reagents. Serum was diluted in MOBS containing 0.05 ~ Tween 20 and 1.0 ~o BSA and added to the plates which were incubated at 4 °C overnight, followed by 1 to 3 h incubation at 37 °C with the optimal concentration of goat anti-mouse immunoglobulin-peroxidase conjugate diluted in MOBS containing 0.05 ~o Tween 20 and 1.0 ~ BSA. The substrate solution consisted of 40 mg of o-phenylenediamine dihydrochloride (Sigma) dissolved in 100 ml citrate-phosphate buffer, pH 5.0 containing 150 ~tl of 30~o hydrogen peroxide. The reaction was allowed to proceed in the dark for 30 rain at room temperature and terminated by the addition of 25 ~tl of 4 M-sulphuric acid. The absorbance of each well was read at 492 nm using a Titertek Multiskan spectrophotometer (Flow Laboratories). The A,,9 2 value for each dilution of serum was plotted (y axis) against the log of its dilution factor (x axis). By fitting a straight line to the plot, the reciprocal value defined by the last dilution preceding the intercept on the x axis was considered to be the serum titre. The expected S.E.M. of triplicate samples was + 6"3 ~ for IgM and 3.7~ for IgG. The goat anti-mouse IgG-peroxidase conjugate could detect all four subclasses of IgG, i.e. IgGl, IgG2a, IgG2b and IgG3 (data not shown).
Neutralization assay. MCMV was diluted in EMEM containing 2~ FCS and mixed with an equal volume of a dilution of heat-treated (56 °C, 30 min) mouse antiserum with complement for 90 min at 37 °C. This mixture was added to washed MEF monolayers and incubated at 37 °C for 1 h. The mixture was then removed and the cells overlaid with EMEM containing 2~ methyl cellulose and 2~o FCS. The cultures were incubated for 5 days at 37 °C and the monolayers were then stained with methylene blue and the plaques counted. The neutralization (plaque reduction) titre of a serum was expressed as the reciprocal of the highest serum dilution that reduced control plaque counts by 50~. In each assay MCMV hyperimmune serum was used at a 1/20 dilution as a control.
Passive antibody transfer. Mice were given 0.5 ml or 1.0 ml (i.p.) of either the immunoglobulin fraction of immune sera from resistant BI0. BR or susceptible BALB/c mice, or MOBS instead of sera and were challenged 24 h later with 3 x 103 p.f.u, of MCMV. Organ homogenates (20~o w/v) were assayed for virus content in the plaque assay.
Interferon assay. Interferon titres were determined by reduction of the c.p.e, caused by encephalomyocarditis virus on L929 cells as described elsewhere (Allan & Shellam, 1985) . A mouse interferon standard (G-002-904-511) was included in every assay and had a mean titre of 1.2 x 104 international reference units/ml (NIH, Bethesda, Md., U.S.A.).
Statistical analysis. Statistical analysis of the data was performed using Student's t-test or by linear correlation.
RESULTS

Parameters of the antibody response: lack of antibodies to MCMV in normal uninfected mice
In contrast to reports of Anderson et aL (1986) that anti-MCMV antibodies were present in the sera of 54.7 ~o of normal mice obtained from commercial breeders in the U.S.A., in this study no antibodies of IgM, IgG or IgA classes were detected by ELISA or neutralization assay of prebleed sera from normal mice of the BALB/c, BALB.K, BALB.B, A/J, CBA, B10, B10.A, BI0.D2 and B10.BR strains. Sera from approximately 20 mice of each strain were tested. Furthermore, no IgM or IgG antibodies to MCMV have been detected by ELISA in the sera of over 300 normal mice tested in this laboratory in the last 4 years. These results support those of Classen et al. (1987) . Thus we have assumed that the mice used in this study had no prior contact with MCMV. 
Parameters of the antibody response. route of inoculation
The route of inoculation of M C M V was found to affect serum antibody ti tres over 21 days p.i. of B 10 mice infected with 104 p.f.u, virulent MCMV. Since higher titres and earlier production of IgM and IgG antibodies were achieved by the i.p. (day 3) compared to the subcutaneous or intranasal routes (days 9 to 11 ; data not shown), the i.p. route was used in all further studies.
Kinetics of anti-MCMV antibody production by susceptible and resistant mouse strains
An ELISA was used to determine total anti-MCMV antibodies of the IgM, IgG and IgA classes in sera of mice inoculated with 3 x 103 p.f.u. MCMV (0.1 BALB/c LDs0).
IgM antibody production was noted as early as 3 days p.i. in B10. D2 and B10. BR mice and by 5 days p.i. in all other strains (Table 1) . There was no correlation between IgM antibody titres and resistance status since, for example, the susceptible BALB.B strain produced more antibody than the highly resistant B10.BR strain within the first week after infection. No detectable IgG antibody was found until day 5 to 7 p.i. (Table 1 ) and again no correlation was observed between resistance status and either the time of first appearance or titre of IgG antibody. In the same sera no detectable IgA antibody was found for any strain tested at any day following MCMV infection by the i.p. route (data not shown).
Kinetics of MCMV titres in liver and spleen of susceptible and resistant mouse strains
To determine whether antibody responses reflected the extent of virus replication in the major target organs, liver and spleen titres of MCMV were determined in the same mice used for antibody studies (Table 2 ). The titres of MCMV were determined from pools of two to three organs and are expressed as log lo p.f.u, per organ rather than per gram of tissue, since the weight of organs was found to vary both between strains and during the course of infection.
Virus titres were detectable by 3 days p.i. in the liver for all strains tested and by 3 days p.i. in the spleen for the most susceptible strains (BALB/c, A/J and BALB. B) but not in the more resistant strains (CBA, B10. A, B 10. D2, B10 and B 10. BR). With the exception of the B10. BR strain, B10 mice and any congenic mice derived from it did not develop virus titres in the spleen until 7 to 10 days p.i. which was approximately 1 week after evidence of virus infection was seen * Virus titres were obtained from two to three pooled organs and were essentially the same following re-titration. t Mice were inoculated with 0.1 LDs0 BALB/c of MCMV (3 × 103 p.f.u.) and were the same animals used for Table 1 and Table 3(b). in the susceptible strains with the BALB/c background. Overall, during the acute phase of this sublethal infection, the pattern of virus growth in resistant and susceptible strains resembled that seen during lethal MCMV disease (Allan & Shellam, 1984) . However, the presence of virus in the spleen and/or liver at 20 days p.i. in B10, B10. D2, B10. BR and A/J mice and its absence in B10.A and CBA mice suggests that acute and persistent infections may be differently regulated by host genetic factors. This deserves further study.
Comparing Tables 1 and 2 , there are statistically significant positive and negative correlations between total IgG antibody titres and the titres to which the virus replicated in the spleen and/or liver amongst individual strains of mice. For example, the strains BALB.B (correlation coefficient r = 0.86) and BALB/c (r = 0.88) produced higher antibody titres with a decrease in plaque titre. However, there was also a linear correlation of increasing antibody titres with increasing plaque titres in other strains including A/J (r = 0.80), B10 (r = 0.77) and B10.D2 (r = 0.75). The overall pattern that emerges is that there is no correlation between the amount of IgM or IgG antibody produced and the virus titre reached in the target organs. Thus, despite high titres of circulating antibody against MCMV, high virus titres may co-exist suggesting that antibody does not play a major role in controlling primary MCMV infections.
Antibody production to salivary gland-derived, attenuated and u.v.-inactivated MCMV
Since virulent MCMV may be immunosuppressive, the induction of anti-MCMV antibody by different forms of the virus was assessed using BALB/c mice inoculated i.p. with either virulent salivary gland-derived virus, attenuated tissue culture-derived virus or u.v.-inactivated virus. Doses of 10, 102, 103 and 104 p.f.u, of virulent or attenuated virus were used. Virus to be u.v.-inactivated had a titre of 10 ~ p.f.u, before inactivation and no detectable titre after inactivation as measured by the plaque assay. .
Both virulent and attenuated forms of MCMV, at all doses tested, elicited production of both IgM (Fig. 1) and IgG (Fig. 2) antibodies. However, the IgM antibody titre elicited by attenuated virus was lower than that produced in response to virulent virus over the dose range of 10 to 103 p.f.u. Interestingly, at doses at or above 10 z p.f.u, of virulent virus the early production of IgM antibody was depressed. Lower amounts of IgM antibody were elicited by u.v.-inactivated virus than either the virulent or the attenuated forms of the virus even when only 10 p.f.u, of these forms of the virus were used (Fig. 1 a, d ). Again, higher IgG titres were obtained when the virus inoculum was virulent rather than attenuated but unlike IgM production there was not an obvious reduction in early IgG titres with increasing doses of MCMV (Fig. 2) , and 104 p.f.u, induced the highest titres (Fig. 2d) . Ultraviolet-inactivated virus was generally a less effective immunogen, although the high titres induced at days 3 and 5 with this form compared with the other forms of the virus suggest that virulent and attenuated viruses may depress the early IgG response to MCMV. Despite the early high titre of antibody induced by u.v.-inactivated virus, the titre did not significantly increase over the 21 days but remained at a low plateau level, probably due to failure of the virus to replicate.
To investigate whether mouse strains of varying resistance status could produce an IgG antibody response to 10 p.f.u, of virulent virus, titres were measured in susceptible A/J (512), BALB/c (2560) and resistant BALB. K (2560), CBA (640) and B10. BR (80) mice at 21 days p.i., a time when peak IgG titres are observed (Table 1) . In contrast with the data in Table 1 , IgG titres were found to correlate inversely with resistance status, with the exception of BALB. K mice. The low antibody titres observed in resistant strains probably reflects limited virus replication in these mice and suggests that antibody titre may only be a useful measure of resistance status when very small doses of virus are used.
Neutralization assay for MCMV ; the requirement for complement
Neutralizing antibody was investigated to assess whether the anti-MCMV antibodies found by ELISA could neutralize the virus. The addition of complement in the neutralization assay with MCMV has been shown to increase the sensitivity of the assay as described by Kim & Carp (1973) , and was investigated here using a hyperimmune mouse antiserum to MCMV and several sources of complement including lyophilized guinea-pig complement or fresh sera from guineapigs, rabbits, B10 or BALB/c mice. The addition of complement markedly reduced the virus titre relative to the virus-antibody mixture without complement, regardless of the source of complement (data not shown), although fresh guinea-pig serum was the most effective (plaque counts of 232 reduced to two with 1/4 dilution of complement). The reduction in virus titre was due to neutralizing antibody in the hyperimmune serum since virus incubated with guinea-pig complement alone (232 plaques) or with antibody and heat-inactivated complement (56 °C, 30 min; 286 plaques) did not neutralize the virus. As both the incubation time and temperature influenced the degree of virus neutralization (data not shown), incubation of the virus-antibody mixture with a 1/8 dilution of fresh guinea-pig sera at 37 °C for 90 min was used for all subsequent assays, unless otherwise stated, since these conditions gave the highest neutralization efficiency.
Neutralizing antibodies to MCMV in resistant and susceptible mouse strains
Although no correlation was found between the total antibody titre determined in the ELISA and the resistance status, the neutralization function of these antibodies was investigated. Neutralization assays were performed on mouse antisera with the use of guinea-pig serum or syngeneic normal mouse serum as a source of complement; this may represent a physiologically more relevant system. Neutralizing antibodies to MCMV were measured in a neutralization assay using virulent (Table 3 a) or attenuated virus (Table 3 b) . Sera from uninfected mice did not contain neutralizing antibodies to either virulent or attenuated virus preparations regardless of the source of complement in the neutralization assay.
First, to assess whether resistance to MCMV correlates with early production of neutralizing antibody, susceptible BALB. B, B10 and resistant BALB. K, B10. BR mice were immunized with 8 × 103 p.f.u, of virulent MCMV; a dose which was lethal for the susceptible strains. All strains failed to produce neutralizing antibody with the use of guinea-pig complement in the t Neutralizing antibody titre expressed as the reciprocal of the highest dilution of pooled sera from five mice giving 50~ reduction of a standard salivary gland-derived MCMV dose (a) or of a standard attenuated MCMV dose (b) with the addition of a 1/8 dilution of guinea-pig complement.
:~ -, All mice were dead at this time. ND, Not done. § Where two values are given the second represents the neutralizing antibody titre expressed as the reciprocal of the highest dilution of pooled sera from five mice giving 50~ reduction of a standard salivary gland-derived MCMV dose (a) or of a standard attenuated MCMV dose (b) with the addition of a 1/8 dilution of syngeneic mouse complement from the same strains from which the antibody was derived. assay, with the exception of the BALB. K strain which produced a low titre at 21 days p.i. only (Table 3 a) . With the use of syngeneic mouse complement instead of guinea-pig complement, no neutralizing antibodies were found in either the BALB. K or the B10. BR strains. Nevertheless, hyperimmune serum obtained from BALB/c mice did neutralize virulent virus and had a titre of 64 with the use of guinea-pig complement and a titre of 16 with the use of syngeneic mouse complement.
In a second experiment, neutralizing antibodies produced in response to sublethal infection with salivary gland-derived MCMV (3 × 103 p.f.u.) were detected much earlier when the virus used in the neutralization assay was attenuated by one passage in tissue culture (Table 3 b ). These sera were the same as those used for the ELISA studies in Table 1 . With the use of guinea-pig complement in the assay, neutralizing antibodies were found as early as 3 days p.i. in all the strains tested (A/J, BALB. B, BALB/c, B10, B10. A, B10. D2, CBA and B10. BR) with maximal titres reached by 7 to 10 days p.i. However, there was no correlation of neutralizing antibody titre with resistance to MCMV since the susceptible BALB/c strain produced higher levels of neutralizing antibody than the resistant CBA and B10. BR strains. In contrast, the neutralizing antibody titres obtained with the use of syngeneic mouse complement were markedly lower than those determined with the addition of guinea-pig complement in BALB/c, A/J, CBA, B10 and B10.BR mice at all the days tested. Thus, mouse complement is less efficient in the neutralization of both virulent and attenuated virus preparations than guinea-pig complement. Again, the neutralizing titre obtained with the addition of mouse complement did not correlate with resistance to MCMV since titres in susceptible BI0 mice were similar to those in resistant B10.BR mice suggesting that neutralizing antibodies may not contribute to genetically determined resistance to MCMV. Hyperimmune sera could neutralize attenuated virus and had a titre of 1280 with the use of guinea-pig complement and again a lower titre (64) was observed with the use of syngeneic mouse complement (data not shown). * Virus titres were obtained from two pooled organs; ND, not determined. t Mice were challenged with 0.1 LDs0 BALB/c of MCMV 24 h after passive transfer with 0.5 ml of the immunoglobulin fraction of immune sera from different donors immunized with 8 x 103 p.f.u, of MCMV by the i.p. route.
:~ Mice were given 1-0 ml of the immunoglobulin fraction of immune sera before virus challenge. § Mice received 0.5 ml of MOBS instead of serum.
The apparent ease of detection of neutralizing antibodies with the use of attenuated rather than virulent MCMV is consistent with the observation that virulent salivary gland-derived MCMV is coated with trypsin-sensitive non-neutralizing antibodies which are capable of blocking the neutralization of MCMV (Chong et al., 1981 ; . Therefore, an investigation of the sensitivity of the virus to trypsin by measurement of neutralization was performed. We observed that the treatment of salivary gland-derived virus with 5 or 10 p.g/ml of trypsin increased the observed neutralizing antibody titre of hyperimmune sera with the addition of guinea-pig complement from 64 to 640 and 2560, respectively, whereas trypsin treatment of attenuated virus did not greatly affect the neutralization titre (data not shown).
Passive transfer of MCMV immunoglobulin
To study the function of the anti-MCMV antibodies in controlling MCMV infection in vivo passive transfer experiments were performed. BALB/c mice were given 5 day, 14 day or 21 day immunoglobulin fractions of immune sera from either resistant B 10. BR or susceptible BALB/c mice i.p. 24 h prior to virus challenge (0.1 LDso, 3 × 103 p.f.u.). Before administration, the immunoglobulin fractions were diluted to the same ELISA titre. At various intervals after virus inoculation, the spleen and liver were assayed for infectious MCMV.
Infectious virus was recovered from all mice receiving MOBS instead of the immunoglobulin fraction of immune serum (Table 4 ). In contrast, mice receiving the MCMV-specific immunoglobulin fraction before viral challenge had significantly reduced virus titres, especially at 3 days p.i. (P ~< 0-0005) in both the spleen and liver, compared to those mice receiving MOBS only. Early fractionated immune serum from B10. BR and BALB/c mice were equally efficient at reducing virus content at day 3, a time when peak virus titres occur in the spleen. Fractionated late immune serum from BALB/c mice was more efficient at reducing splenic virus titres than late fractionated immune serum from B10.BR mice. However, when the amount of immunoglobulin passively transferred from either BALB/c or B 10. BR mice was increased from 0-5 to 1-0 ml, virus titres were in general more markedly reduced.
The reduced virus titres in the recipients were not due to the presence of interferon since all fractionated sera contained less than 2 international units of interferon/0.1 ml (data not shown).
DISCUSSION
Normal uninfected mice did not produce anti-MCMV antibody as detected by ELISA and the neutralization assay. Thus normal mice were not infected with MCMV. The observations presented in this study suggest that anti-MCMV antibodies produced in MCMV-infected mice as detected by these assays do not correlate with the level of resistance of the mouse strain to the virus.
Virus titres were shown to influence the amount of antibody detected by the ELISA as seen for example at day 10 p.i. with susceptible BALB. B and A/J mice producing more IgG antibody with higher virus titres in the liver and the spleen than did resistant B10.BR and B10.D2 animals. Overall, there was a general trend towards higher titres in the liver and spleen of the more susceptible strains with greatest production of antibody in those strains which developed the highest levels of virus in these organs. For example, susceptible BALB. B mice produced IgG levels of 40960 and virus titres of 4.20 loglo p.f.u./spleen and 4.85 log10 p.f.u./liver whereas resistant B 10. BR mice did not produce high titres of IgM or IgG and had low titres in the spleen and liver during the 20 days after infection. Thus, despite high titres of circulating antibody, high virus titres also exist. MCMV-infected mice did not produce IgA anti-MCMV antibodies which may be due to the i.p. route of inoculation since IgA is usually produced in mucosal surfaces after intranasal administration.
Both attenuated and u.v.-inactivated MCMV elicited antibody of the IgM and IgG classes but the titre was always less than that observed with virulent salivary gland-derived virus. Hence the virus must be fully infectious in order to induce high antibody titres. The lower antibody titres produced in mice immunized with inactivated virus probably reflects a lack of virus replication and is consistent with results obtained with other viruses (Rosenberg & Notkins, 1974) .
The requirement for complement in the neutralization assay for MCMV confirms the results of Kim & Carp (1973) , and supports observations with other viruses, including human cytomegalovirus, herpes simplex virus type 1, simian cytomegalovirus and rubella virus which are also neutralized more efficiently by antibody after the addition of complement (Masuho et al., 1987; Yoshino & Taniguchi, 1965) . Although the role of complement is generally attributed to an increase in the bulk of protein on the virion surface which hinders absorption, it may enhance virus neutralization by directly lysing the virus-antibody mixture as has been shown for many enveloped viruses including avian infectious bronchitis virus (Berry & Almeida, 1968) , mouse leukaemia virus (Oroszlan & Gilden, 1970) , Moloney leukaemia virus (Oldstone, 1975) and rubella virus (Schluederberg et al., 1976) . In addition, complement may enhance neutralization by facilitating the agglutination of antibody-coated virions (Oldstone et al., 1974) .
Araullo-Cruz et al. (1978) found that in the presence of complement, neutralizing antibodies could be detected as early as 3 to 5 days p.i. in outbred CD1 mice. However, the titres were very low, being 1/4 to 1/8 for 50 % plaque reduction. The results presented in this study provide evidence for the existence of early neutralizing antibodies to MCMV in both resistant and susceptible mouse strains. However, since the titre of neutralizing antibody did not correlate with the patterns of resistance, the results suggest that neutralizing antibodies are unimportant as mediators of genetically controlled resistance to MCMV. These findings support the observations of Grundy (Chalmer) et al. (1981) who concluded that neutralizing antibodies were not involved in the increased resistance of C3H and BALB. K mice compared to BALB/c mice.
The apparent ease of detection of neutralizing antibodies with the use of attenuated rather than virulent MCMV is consistent with the observation that virulent salivary gland-derived MCMV is coated with non-neutralizing antibody (Chong et al., 1981 ; Inada & Mires, 1985) . Therefore, perhaps the non-neutralizing antibody is competing with and hence blocking the action of serum anti-MCMV neutralizing antibody. Treatment of salivary gland-derived virus with trypsin increased the observed neutralizing antibody titre of hyperimmune sera with the addition of guinea-pig complement whereas trypsin treatment of attenuated virus did not greatly affect the neutralization titre. These results support the findings of Inada & Mires (1985) that a trypsin-sensitive factor is associated with virulence of the virus and appears to hinder virus neutralization. The observation that virus obtained from infected tissues at an early stage of infection (3 to 5 days p.i.) can be more readily neutralized by antibody and complement than virus obtained late in infection (Eizuru & Minamishima, 1979; Chong et al., 1981) may reflect the fact that the virus obtained after 5 days p.i. is coated with non-neutralizing antibody which is capable of blocking the action of neutralizing antibody produced in the animal. Thus, the action of neutralizing antibodies to MCMV may be physically interfered with by the production of other anti-MCMV antibodies.
Passive transfer of immune serum significantly lowered virus titres in the spleen and liver of infected recipients regardless of the donor's resistance status to MCMV. The reduced virus titres in the recipients was not due to the presence of IFN in the transferred serum. A corresponding result was found by Araullo-Cruz et al. (1978) in passive immunization experiments using 3 to 5 day immune antisera from CD1 mice. The protective factor was found to be specific immunoglobulin and not interferon since fractionated immunoglobulin contains little interferon (Shanley et al., 1981) and the passive transfer of interferon does not protect (Araullo-Cruz et aL, 1978) . However, immune serum passively transferred before virus inoculation can not prevent the establishment of infection or the subsequent development of viral latency (Shanley et al., 1981) . Thus, antibody must be present before virus infection if it is to play a role in resistance. Nevertheless, MCMV and human cytomegalovirus can reactivate despite the presence of circulating antibody (Medearis, 1964; Hanshaw, 1968) and the virus can spread from cell to cell even in the presence of extracellular viral antibody (Notkins, 1974) .
In conclusion, specific antibodies to MCMV are produced in both resistant and susceptible mouse strains. The lack of a positive correlation of resistance status with either total or neutralizing antibody found early in infection suggests that the antibody response to MCMV does not account for the genetically determined differences in resistance of mice to MCMV.
Finally, should the determination of antibody to HCMV in man be of diagnostic value, our data suggest that antibody titres per se may not be a reliable measure of the genetically determined resistance status of the host. This work was supported by a grant from the National Health and Medical Research Council of Australia.
